Leah J Hogdal
Overview
Explore the profile of Leah J Hogdal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
812
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cojocari D, Smith B, Purkal J, Arrate M, Huska J, Xiao Y, et al.
Haematologica
. 2021 Apr;
107(4):825-835.
PMID: 33853293
Dysregulation of apoptotic machinery is one mechanism by which acute myeloid leukemia (AML) acquires a clonal survival advantage. B-cell lymphoma protein-2 (BCL2) overexpression is a common feature in hematologic malignancies....
2.
Ramsey H, Fischer M, Lee T, Gorska A, Arrate M, Fuller L, et al.
Cancer Discov
. 2018 Sep;
8(12):1566-1581.
PMID: 30185627
Suppression of apoptosis by expression of antiapoptotic BCL2 family members is a hallmark of acute myeloblastic leukemia (AML). Induced myeloid leukemia cell differentiation protein (MCL1), an antiapoptotic BCL2 family member,...
3.
Montero J, Stephansky J, Cai T, Griffin G, Cabal-Hierro L, Togami K, et al.
Cancer Discov
. 2016 Dec;
7(2):156-164.
PMID: 27986708
Significance: Therapy for BPDCN is inadequate, and survival in patients with the disease is poor. We used primary tumor cell functional profiling to predict BCL2 antagonist sensitivity as a common...
4.
Lee T, Bian Z, Zhao B, Hogdal L, Sensintaffar J, Goodwin C, et al.
FEBS Lett
. 2016 Nov;
591(1):240-251.
PMID: 27878989
Pdb Id Codes: Comp. 2: 5IEZ; Comp. 5: 5IF4.
5.
Bhola P, Mar B, Lindsley R, Ryan J, Hogdal L, Vo T, et al.
J Clin Invest
. 2016 Sep;
126(10):3827-3836.
PMID: 27599292
Upfront resistance to chemotherapy and relapse following remission are critical problems in leukemia that are generally attributed to subpopulations of chemoresistant tumor cells. There are, however, limited means for prospectively...
6.
Pan R, Hogdal L, Benito J, Bucci D, Han L, Borthakur G, et al.
Cancer Discov
. 2013 Dec;
4(3):362-75.
PMID: 24346116
B-cell leukemia/lymphoma 2 (BCL-2) prevents commitment to programmed cell death at the mitochondrion. It remains a challenge to identify those tumors that are best treated by inhibition of BCL-2. Here,...
7.
Hogdal L, Letai A
Cell Stem Cell
. 2013 Mar;
12(3):269-70.
PMID: 23472867
Leukemia stem cells (LSCs) are likely to be the source for both therapeutic resistance and relapse in myeloid malignancies. As reported in this issue of Cell Stem Cell, Lagadinou et ...
8.
Ahlenstiel G, Edlich B, Hogdal L, Rotman Y, Noureddin M, Feld J, et al.
Gastroenterology
. 2011 Jul;
141(4):1231-9, 1239.e1-2.
PMID: 21741920
Background & Aims: Mathematical modeling of hepatitis C virus (HCV) kinetics indicated that cellular immune responses contribute to interferon (IFN)-induced clearance of HCV. We investigated a potential role of natural...
9.
Edlich B, Hogdal L, Rehermann B, Behrens S
Vaccine
. 2010 Oct;
28(49):7764-73.
PMID: 20887827
Antigen-specific T cells can be induced by direct priming and cross-priming. To investigate cross-priming as a vaccination approach dendritic cells were transfected with cytopathogenic viral RNA-replicons that expressed domains of...